MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00135863
Recruitment Status : Terminated
First Posted : August 26, 2005
Last Update Posted : May 21, 2015
LEO Pharma
Coloplast A/S
Information provided by:
Ribe County Hospital

August 25, 2005
August 26, 2005
May 21, 2015
May 2004
Not Provided
Grade of inflammation, local and systemic
Same as current
Complete list of historical versions of study NCT00135863 on Archive Site
  • Vascular compliance
  • Nutritional state
  • Efficacy of Peritoneal Dialysis
  • Change in local cellular distribution
  • Change in local and systemic generation of thrombi
Same as current
Not Provided
Not Provided
MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis
Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis
Patients with end stage renal disease (ESRD) who use peritoneal dialyses with Physioneal(R) (Baxter A/S, Denmark) were allocated to inject either placebo or tinzaparin daily into the morning dialysis bag. Active medication, as well as placebo, was added for three months separated by a one month washout period. At the beginning and end of each treatment period peritoneal equilibrations tests (PE-tests), Kt/V, blood and dialysate samples were analyzed. We, the researchers at Ribe County Hospital, set out to examine inflammation (local and systemic), nutrition and ultrafiltration.
Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
  • Inflammation
  • Nutrition
  • Peritoneal Dialysis
Drug: tinzaparin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2005
Not Provided

Inclusion Criteria:

  • End stage renal disease
  • Peritoneal dialysis without complication for minimum of three months
  • 18 years or above
  • Informed consent

Exclusion Criteria:

  • Known coagulatory defects including anticoagulation therapy
  • Known bleeding tendency
  • Peritonitis within two months prior to inclusion
  • Pregnancy
  • Breast feeding
  • Active infection
  • Non-informed consent
  • Allergy to heparin or prior heparin induced thrombocytopenia
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
MesoHep II
Not Provided
Not Provided
Not Provided
Not Provided
Ribe County Hospital
  • LEO Pharma
  • Coloplast A/S
Study Chair: Robert S Petersen, MD Ribe County Hospital, Department of Nephrology
Principal Investigator: Mikkel B Rasmussen, MD Ribe County Hospital, Department of Nephrology
Ribe County Hospital
January 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP